Department of Neurology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
J Int Med Res. 2020 Mar;48(3):300060519867490. doi: 10.1177/0300060519867490. Epub 2019 Nov 10.
Miller Fisher syndrome (MFS), a variant of Guillain-Barré syndrome, is characterized by ataxia, areflexia and ophthalmoplegia. This case report describes a 40-year old male that presented with a 3-day history of unsteady walking and numbness on both hands, and a 2-day history of seeing double images and unclear articulation. Lumbar puncture revealed an opening pressure of 260 mm HO. Plasma serology was positive for anti-ganglioside M1-immunoglobulin M (anti-GM1-IgM) antibodies and negative for anti-ganglioside Q1b (anti-GQ1b) antibodies. The patient was diagnosed with MFS based on the clinical course and neurophysiological findings. On the 4th day of treatment with intravenous immunoglobulin (IVIG), his ataxia and unsteady walking improved, but his bilateral eyeballs were fixed, and over the next few days he developed bilateral peripheral facial paralysis. After 5 days of IVIG treatment, methylprednisolone treatment was offered and the patient's symptoms gradually improved. Early intracranial hypertension and delayed facial nerve palsy may be atypical presentations of MFS. Anti-GM1-IgM antibodies may be the causative antibodies for MFS. If the IVIG therapy does not stop the progression of the disease, the addition of corticosteroid therapy may be effective. However, the relationship between IgM type, anti-GM1 antibody and MFS remains unclear and requires further research.
米勒费舍尔综合征(MFS)是吉兰-巴雷综合征的一种变异型,其特征为共济失调、反射消失和眼肌麻痹。本病例报告描述了一名 40 岁男性,他有 3 天的不稳行走和双手麻木病史,以及 2 天的复视和言语不清病史。腰椎穿刺显示开放压力为 260 毫米水柱。血浆血清学检查抗神经节苷脂 M1-免疫球蛋白 M(抗 GM1-IgM)抗体阳性,抗神经节苷脂 Q1b(抗 GQ1b)抗体阴性。根据临床过程和神经生理学发现,该患者被诊断为 MFS。在静脉注射免疫球蛋白(IVIG)治疗的第 4 天,他的共济失调和不稳行走改善,但他的双眼球固定,接下来几天他出现双侧周围性面瘫。在 IVIG 治疗 5 天后,给予甲基强的松龙治疗,患者的症状逐渐改善。早期颅内压增高和迟发性面神经麻痹可能是 MFS 的不典型表现。抗 GM1-IgM 抗体可能是 MFS 的致病抗体。如果 IVIG 治疗不能阻止疾病的进展,加用皮质类固醇治疗可能有效。然而,IgM 型、抗 GM1 抗体与 MFS 之间的关系尚不清楚,需要进一步研究。